GlassScriptPhysician profile
Mckenzie Rose Comba
NPI 1548810575
$9,360.34
in general payments reported to CMS, 2019-2025
62 companies · $2,798 in 2025
The $2,798 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $377 · 2022: $1,904 · 2023: $1,877 · 2024: $2,406 · 2025: $2,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,775 · Education: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,775.04 |
| Education | $304.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,094.35 | 2022-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $798.55 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $546.07 | 2022-2025 | Piqray |
| Merck Sharp & Dohme LLC | $542.36 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $483.48 | 2022-2025 | Darzalex, Erleada, Akeega |
| Astellas Pharma US INC | $409.19 | 2021-2025 | Padcev, Vyloy, Xospata |
| Daiichi Sankyo INC. | $362.49 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Seagen INC. | $320.06 | 2022-2025 | Adcetris, Padcev |
| Lilly USA, LLC | $239.40 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $237.52 | 2022-2025 | Ninlaro, Fruzaqla, Vpriv |
| Incyte Corporation | $233.91 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $200.45 | 2021-2025 | |
| Pfizer INC. | $197.92 | 2023-2025 | |
| Eisai INC. | $189.87 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $183.61 | 2022 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $183.26 | 2021-2025 | Libtayo |
| Array Biopharma INC | $181.51 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Ipsen Biopharmaceuticals, INC | $166.06 | 2022-2025 | Onivyde, Tazverik |
| Celgene Corporation | $158.68 | 2022-2024 | Pomalyst, Reblozyl |
| Coherus Oncology, INC. | $156.85 | 2024-2025 | Loqtorzi |
| Genentech USA, INC. | $153.26 | 2022-2024 | Phesgo, Polivy, Perjeta |
| Amgen INC. | $149.18 | 2021-2023 | Lumakras, Vectibix, Xgeva |
| Deciphera Pharmaceuticals INC. | $146.02 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Emd Serono, INC. | $136.25 | 2021-2025 | |
| Springworks Therapeutics, INC. | $136.07 | 2024-2025 | Ogsiveo |
| Glaxosmithkline, LLC. | $122.71 | 2021-2025 | Jemperli, Zejula, Blenrep |
| Tersera Therapeutics LLC | $98.42 | 2023-2025 | Zoladex |
| Servier Pharmaceuticals LLC | $94.86 | 2022-2025 | |
| Genzyme Corporation | $89.25 | 2021-2024 | |
| Aveo Pharmaceuticals, INC. | $86.12 | 2022 | |
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 | |
| Sobi, INC | $84.71 | 2023-2025 | |
| Gilead Sciences, INC. | $84.11 | 2022-2024 | Trodelvy |
| Mirati Therapeutics, INC. | $83.53 | 2023-2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $81.05 | 2021-2023 | Imbruvica |
| Kyowa Kirin, INC. | $73.98 | 2023-2025 | Poteligeo |
| Exelixis INC. | $61.12 | 2023-2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $59.62 | 2022-2023 | Rezlidhia, Tavalisse |
| Stemline Therapeutics INC. | $59.18 | 2024-2025 | Orserdu |
| Iovance Biotherapeutics, INC. | $49.90 | 2025 | Amtagvi |
| Alexion Pharmaceuticals, INC. | $48.11 | 2024 | Ultomiris |
| Sumitomo Pharma America, INC. | $44.16 | 2024-2025 | Orgovyx |
| Taiho Oncology, INC. | $41.71 | 2022-2024 | |
| Azurity Pharmaceuticals, INC. | $39.14 | 2024 | Vivimusta |
| Aimmune Therapeutics, INC. | $34.02 | 2025 | Zenpep |
| Spectrum Pharmaceuticals INC. | $29.20 | 2023 | Rolvedon |
| Beigene USA, INC. | $27.95 | 2023 | Brukinsa |
| Genmab U.S., INC. | $25.38 | 2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $22.83 | 2025 | |
| Octapharma USA, INC. | $21.92 | 2023 | Panzyga |
| Blue Earth Diagnostics | $20.87 | 2025 | Posluma |
| Geron Corporation | $20.01 | 2025 | Rytelo |
| Blueprint Medicines Corporation | $18.89 | 2025 | Ayvakit |
| Pharmaessentia USA Corporation | $18.37 | 2023 | Besremi |
| Apellis Pharmaceuticals, INC. | $17.77 | 2024 | Empaveli |
| Cti Biopharma Corp. | $17.43 | 2022 | |
| Tempus Ai, INC | $17.22 | 2025 | Xt Cdx |
| Ferring Pharmaceuticals INC. | $16.99 | 2025 | Adstiladrin |
| Kite Pharma, INC. | $16.88 | 2021 | |
| Medtronic, INC. | $15.07 | 2021 | |
| Caris Mpi, INC. | $14.20 | 2025 | Mi Cancer Seek |
| Organon LLC | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenzie Comba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.